Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Advanced Medical Cancer Therapy
March 29 2019 - 9:00AM
via NetworkNewsAudio – Genprex Inc. (NASDAQ:GNPX) announces
the availability of a NetworkNewsAudio publication titled,
“Advanced Medical Technologies Provides Unprecedented Targeting in
Cancer Therapy.”
To hear the NetworkNewsWire Audio version,
visit: http://nnw.fm/XRt4d
To read the full editorial, visit: http://nnw.fm/tB7Li
A multiplicity of potential breakthrough treatments to fight
cancer are in varying stages of clinical development, and many are
focused on the promise of advanced gene therapies. Genprex
Inc. (NASDAQ: GNPX) (GNPX
Profile) is working to bring its
potentially life-changing immunogene therapy, Oncoprex, to
market.
Genprex already has 30 issued patents for its platform
technologies and gene therapies. The company’s Oncoprex immunogene
therapy combined with the targeted therapy erlotinib is in the
Phase II portion of a Phase I/II clinical trial, and the
combination of Oncoprex with immunotherapies is in preclinical
development. The company is also conducting research to find
biomarkers to identify patients most likely to benefit from Genprex
treatments, as well as other drugs that will be synergistic with
Genprex gene therapies.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company’s web site at www.genprex.com or
follow Genprex on Twitter at twitter.com/genprex, Facebook at
facebook.com/genprexinc, and LinkedIn at
linkedin.com/company/genprex.
About NetworkNewsAudio
NetworkNewsAudio (NNA) , a NetworkNewsWire (NNW) Solution,
allows you to sit back and listen to market updates, CEO interviews
and a Company AudioPressRelease (APR). These audio clips provide
snapshots of position, opportunity and
momentum. NetworkNewsAudio (NNA) can assist your company
by cutting through the overload of information in today's market,
NNA brings its clients unparalleled visibility, recognition and
brand awareness. NetworkNewsWire (NNW) is where news,
content and information converge. NetworkNewsWire
(NNW) is a comprehensive provider of news aggregation and
syndication, enhanced press release services and a full array of
social communication solutions. As a multifaceted financial news
and distribution company with an extensive team of journalists and
writers, NNW has the unparalleled ability to reach a wide audience
of investors, consumers, journalists and the general public with an
ever-growing distribution network of more than 5,000 key
syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Sep 2023 to Sep 2024